Patents Assigned to The Regents of the Univ. of California
  • Publication number: 20220348737
    Abstract: The present invention provides: nanoparticles including a compound that includes porous silica and at least one high-atom selected from the group consisting of gadolinium atoms, iodine atoms, gold atoms, silver atoms, and platinum atoms; and a pharmaceutical composition for radiation treatment, useful for treatment of solid tumors, etc., and including these nanoparticles and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: September 25, 2020
    Publication date: November 3, 2022
    Applicants: KYOTO UNIVERSITY, NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY, THE REGENTS OF THE UNIV. OF CALIFORNIA
    Inventors: Fuyuhiko TAMANOI, Kotaro MATSUMOTO, Hiroyuki SAITOH, Ayumi SENOUCHI, Toshiki TAJIMA
  • Patent number: 6872817
    Abstract: Methods and compositions for chromosome-specific staining are provided. Compositions comprise heterogeneous mixtures of labeled nucleic acid fragments having substantially complementary base sequences to unique sequence regions of the chromosomal DNA for which their associated staining reagent is specific. Methods include methods for making the chromosome-specific staining compositions of the invention, and methods for applying the staining compositions to chromosomes.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: March 29, 2005
    Assignee: The Regents of the Univ. of California
    Inventors: Joe W. Gray, Daniel Pinkel
  • Publication number: 20040167014
    Abstract: A novel proton exchange membrane fuel cell with nanostructured components with higher precious metal utilization rate at the electrodes, higher power density, and lower cost. Aligned arrays of carbon nanotubes, either single wall or multiwall, are prepared by catalyzed chemical vapor deposition (CVD), or plasma assisted CVD and used as support for catalyst. Solubilized perfluorosulfonate ionomer membrane is incorporated into the spare space between nanotubes to form a 4-phase boundary of gas, metal, proton conductor, and electron conductor. By assembling the as-prepared electrodes with perfluorosulfonate ionomer membrane, backing layers and electron collectors, proton exchange membrane fuel cells are developed.
    Type: Application
    Filed: November 13, 2003
    Publication date: August 26, 2004
    Applicant: The Regents of the Univ. of California, Office of Technology Transfer, University of California
    Inventors: Yushan Yan, Cheng Wang
  • Patent number: 6544528
    Abstract: The subject invention pertains to novel methods and compositions for protecting cats from infection by a broad range of FIV strains using a multi-subtype FIV vaccine. Multi-subtype FIV vaccines comprising either cell free whole virus or cell lines infected with viruses are described. Methods for vaccinating cats with the subject vaccine compositions are also described. Cats vaccinated according to the methods and compositions of the subject invention exhibit protective humoral and cellular immune responses to FIV when challenged with homologous or heterologous strains of FIV. The subject invention also pertains to novel feline cell lines that are susceptible to infection by FIV and their methods of use.
    Type: Grant
    Filed: November 7, 2000
    Date of Patent: April 8, 2003
    Assignees: University of Florida Research Foundation, Inc., Regents of the Univ. of California
    Inventor: Janet K. Yamamoto
  • Patent number: 6349649
    Abstract: The perforating device for use in completing a well includes a case, an explosive charge contained in the case, and a generally bowl-shaped liner. The liner is positioned adjacent the explosive charge and has non-uniforrn thickness along its length. The liner further includes a protruding portion near its tip. In another configuration, the liner includes a hole near its tip to expose a portion of the explosive charge.
    Type: Grant
    Filed: September 13, 1999
    Date of Patent: February 26, 2002
    Assignees: Schlumberger Technology Corp., Regents of Univ. of California
    Inventors: Jerome J. Jacoby, James E. Brooks, Clifford L. Aseltine
  • Patent number: 6277593
    Abstract: Novel dorsal growth inducing factors, complexes including the factors, and DNA or RNA coding sequences for the factors are described.
    Type: Grant
    Filed: October 7, 1998
    Date of Patent: August 21, 2001
    Assignees: Regeneron Pharmaceuticals, Inc., Regents of the Univ. of California
    Inventors: David M. Valenzuela, Nancy Y. Ip, Henryk D. Cudny, George D. Yancopoulos, Richard M. Harland, William C. Smith, Teresa Lamb, Anne Knecht
  • Patent number: 6274119
    Abstract: A method for labeling &bgr;-amyloid plaques and neurofibrillary tangles in vivo and in vitro, comprises contacting a compound of formula (I): with mammalian tissue.
    Type: Grant
    Filed: August 20, 1999
    Date of Patent: August 14, 2001
    Assignee: The Regents of the Univ. of California
    Inventors: Jorge R. Barrio, Andrej Petric, Nagichettiar Satyamurthy, Gary W. Small, Gregory M. Cole, Sung-Cheng Huang
  • Patent number: 6262254
    Abstract: An efficient, regiocontrolled approach to the synthesis of 8-fluoropurines by direct fluorination of purines with dilute elemental fluorine, or acetyl hypofluorite, is provided. In a preferred embodiment, a purine compound is dissolved in a polar solvent and reacted with a dilute mixture of F2 in He or other inert gas.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: July 17, 2001
    Assignee: The Regents of Univ. of California
    Inventors: Jorge R. Barrio, Nagichettiar Satyamurthy, Mohammad Namavari, Michael E. Phelps
  • Patent number: 6166039
    Abstract: Methods for treatment of peripheral hyperalgesia are provided, comprising administering compositions containing an anti-hyperalgesia effective amount of one or more compounds that directly or indirectly interact with peripheral opiate receptors, but that do not, upon topical or local administration, elicit central nervous system side effects. The anti-diarrheal compound 4-(.rho.-chlorophenyl)-4-hydroxy-N-N-dimethyl-.alpha.,.alpha.-diphenyl-1-p iperidinebutyramide hydrochloride is preferred for use in the methods.
    Type: Grant
    Filed: November 24, 1998
    Date of Patent: December 26, 2000
    Assignee: Regents of the Univ. of California
    Inventor: Tony L. Yaksh
  • Patent number: 6090811
    Abstract: A novel use for the class of biologically active bis-heterocyclic, e.g., bis-indole alkaloid compounds, which have been named topsentins, bromotopsentins, homocarbonyltopsentins, nortopsentins, hamacanthins, bis-indole ethylamines, or dragmacidins, pharmaceutical compositions containing the compounds, methods of producing the compounds, and methods of using the compounds are disclosed. Specifically, the novel utility pertains to the anti-neurogenic inflammatory properties exhibited by the bis-indole compounds and their analogs.
    Type: Grant
    Filed: July 16, 1999
    Date of Patent: July 18, 2000
    Assignees: Harbor Branch Oceanographic Institution, Inc., Regents of the Univ. of California
    Inventors: Robert S. Jacobs, Shirley A. Pomponi, Sarath P. Gunasekera, Amy E. Wright
  • Patent number: 6074835
    Abstract: The present invention provides a method of diagnosing ulcerative colitis (UC) in a subject suspected of having inflammatory bowel disease by by obtaining a sample from the individual; contacting the sample with human histone H1, or pANCA-reactive fragment thereof, under conditions suitable to form a complex of human histone H1, or pANCA-reactive fragment thereof, and antibody to human histone H1; and detecting the presence or absence of the complex, where the presence of the complex indicates that the individual has UC. The invention also provides related methods of diagnosing a perinuclear anti-neutrophil cytoplasmic antibody positive (pANCA-positive) clinical subtype of UC in a patient with UC. In addition, the invention further provides methods of determining susceptibility to UC in an individual.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: June 13, 2000
    Assignees: Regents of the Univ. of California, Cedars-Sinai Medical Center
    Inventors: Johnathan Braun, Stephan R. Targan, Mark Eggena
  • Patent number: 6075007
    Abstract: Described are modified Noggin muteins, compositions comprising the muteins, and DNA or RNA sequences comprising coding (sense) or antisense sequences for the muteins.
    Type: Grant
    Filed: July 17, 1997
    Date of Patent: June 13, 2000
    Assignees: Regeneron Pharmaceuticals, Inc., Regents of the Univ. of California
    Inventors: Aris Economides, Neil E. Stahl, Richard M. Harland
  • Patent number: 5955462
    Abstract: A novel use for the class of biologically active bis-heterocyclic, e.g., bis-indole alkaloid compounds, which have been named topsentins, bromotopsentins, homocarbonyltopsentins, nortopsentins, hamacanthins, bis-indole ethylamines, or dragmacidins, pharmaceutical compositions containing the compounds, methods of producing the compounds, and methods of using the compounds are disclosed. Specifically, the novel utility pertains to the anti-neurogenicinflammatory properties exhibited by the bis-indole compounds and their analogs.
    Type: Grant
    Filed: October 31, 1997
    Date of Patent: September 21, 1999
    Assignees: Harbor Branch Oceanographic Institution, Inc., Regents of the Univ. of California
    Inventors: Robert S. Jacobs, Shirley A. Pomponi, Sarath P. Gunasekera, Amy E. Wright
  • Patent number: 5821124
    Abstract: Novel dorsal growth inducing factors, complexes including the factors, and DNA or RNA coding sequences for the factors are described. Hybridoma cell lines and antibodies that bind to the dorsal growth inducing factor noggin, having the amino acid sequence set forth in SEQ ID NO:2, are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 13, 1998
    Assignees: Regeneron Pharmaceuticals, Inc., Regents of Univ. of California
    Inventors: David M. Valenzuela, George D. Yancopoulos, Richard M. Harland, William C. Smith
  • Patent number: 5667968
    Abstract: Photoreceptor injury or cell death (retinal degeneration) is prevented by the introduction into the living mammalian eye of specific, survival-promoting factors. These specific factors prevent damage and degeneration of photoreceptors when introduced into the living eye prior to, during or after exposure to the damaging effects of light and delay photoreceptor damage caused by inherited disease.
    Type: Grant
    Filed: November 4, 1994
    Date of Patent: September 16, 1997
    Assignees: Regeneron Pharmaceuticals, Inc., Regents of the Univ. of California
    Inventors: Matthew M. LaVail, Roy H. Steinberg, George D. Yancopoulos
  • Patent number: 5589881
    Abstract: A low-noise FET amplifier is connected to amplify output charge from a che coupled device (CCD). The FET has its gate connected to the CCD in common source configuration for receiving the output charge signal from the CCD and output an intermediate signal at a drain of the FET. An intermediate amplifier is connected to the drain of the FET for receiving the intermediate signal and outputting a low-noise signal functionally related to the output charge signal from the CCD. The amplifier is preferably connected as a virtual ground to the FET drain. The inherent shunt capacitance of the FET is selected to be at least equal to the sum of the remaining capacitances.
    Type: Grant
    Filed: November 9, 1994
    Date of Patent: December 31, 1996
    Assignee: The Regents of the Univ. of California Office of Technology Transfer
    Inventors: Mark E. Dunham, David W. Morley
  • Patent number: 5581566
    Abstract: A system of sending and receiving gateways interconnects high speed data interfaces, e.g., HIPPI interfaces, through fiber optic links, e.g., a SONET network. An electronic stripe distributor distributes bytes of data from a first interface at the sending gateway onto parallel fiber optics of the fiber optic link to form transmitted data. An electronic stripe collector receives the transmitted data on the parallel fiber optics and reforms the data into a format effective for input to a second interface at the receiving gateway. Preferably, an error correcting syndrome is constructed at the sending gateway and sent with a data frame so that transmission errors can be detected and corrected in a real-time basis. Since the high speed data interface operates faster than any of the fiber optic links the transmission rate must be adapted to match the available number of fiber optic links so the sending and receiving gateways monitor the availability of fiber links and adjust the data throughput accordingly.
    Type: Grant
    Filed: January 6, 1995
    Date of Patent: December 3, 1996
    Assignee: The Regents of the Univ. of California Office of Technology Transfer
    Inventors: Wallace B. St. John, David H. DuBois
  • Patent number: 5578909
    Abstract: A coupled-cavity drift-tube linac (CCDTL) combines features of the Alvarez drift-tube linac (DTL) and the .pi.-mode coupled-cavity linac (CCL). In one embodiment, each accelerating cavity is a two-cell, 0-mode DTL. The center-to-center distance between accelerating gaps is .beta..lambda., where .lambda. is the free-space wavelength of the resonant mode. Adjacent accelerating cavities have oppositely directed electric fields, alternating in phase by 180 degrees. The chain of cavities operates in a .pi./2 structure mode so the coupling cavities are nominally unexcited. The CCDTL configuration provides an rf structure with high shunt impedance for intermediate velocity charged particles, i.e., particles with energies in the 20-200 MeV range.
    Type: Grant
    Filed: July 15, 1994
    Date of Patent: November 26, 1996
    Assignee: The Regents of the Univ. of California
    Inventor: James H. Billen
  • Patent number: 5571675
    Abstract: Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: November 5, 1996
    Assignees: Genentech, Inc., Regents of the Univ. of California
    Inventors: Joffre Baker, Kenneth Chien, Kathleen King, Diane Pennica, William Wood
  • Patent number: 5571893
    Abstract: Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed, These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: November 5, 1996
    Assignees: Genentech, Inc., Regents of the Univ. of California
    Inventors: Joffre Baker, Kenneth Chien, Kathleen King, Diane Pennica, William Wood